Dr. Aubrey de Grey reveals why reversing aging may be easier than slowing it down in this mind-expanding conversation that challenges conventional wisdom about human longevity. The renowned biomedical gerontologist outlines his damage repair approach that’s gaining mainstream scientific acceptance after initial skepticism.

The financial landscape of longevity research has dramatically transformed, with billions flowing into the space. Dr. de Grey provides an insider’s assessment of major players including HEvolution (Saudi-backed), Altos Labs (Bezos-funded), Calico (Google-funded) and Retro Biosciences (Sam Altman’s venture), offering candid insights about which approaches show the most promise and why Google’s Calico has struggled despite substantial resources.

Regulatory innovation emerges as a crucial accelerator for progress. Montana’s groundbreaking expansion of Right to Try legislation now allows anyone to access treatments that have passed FDA safety trials, while special economic zones like Prospera in Honduras are creating regulatory environments specifically designed for biomedical innovation. These developments could create the competitive pressure needed to modernize traditional regulatory structures worldwide.

At the LEV Foundation, Dr. de Grey is conducting a thousand-mouse study combining four different damage repair interventions in middle-aged mice, aiming for a full year of life extension—far beyond the four months typically achieved. Unlike conventional approaches that rely on dietary modifications, this ambitious project incorporates advanced cell and gene therapies that target multiple forms of age-related damage simultaneously.

Looking forward, Dr. de Grey offers his characteristic probabilistic prediction: a 50–50 chance of reaching \.